Receipt date: 08/28/2009

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)

SHEET 1 OF 1

	PTO/SB/08 Equivalent
Application No.	09/646,950
Filing Date	December 8, 2000
First Named Inventor	Watts, Colin
Art Unit	1644
Examiner	VanderVegt, Francois P.
Attorney Docket No.	ERP01.004APC

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,608,057 B2	08-19-2003	Cywin et al.	

-	FOREIGN PATENT DOCUMENTS						
-	Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T¹

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T¹
	2	ALTERI E et al. 1993 "CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral pativity." Antimicrob Aconto Chamather 37:2087	
		2092.	
	3	MANOURY B. et al. 2002 "Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP" Nature Immunology 3:169-174.	
	4	RIESE, R.J. et al. 1998 "Cathepsin S activity regulates antigen presentation and immunity" J Clin Invest 101:2351-2363.	

7721934 082709

Examiner Signature	/Thomas Heard/	Date Considered	03/16/2010	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.